UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 28, 2005
DUSA PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
NEW JERSEY 0-19777 22-3103129
(State or other (Commission File (IRS Employer
jurisdiction of Number) Identification
incorporation) Number)
25 UPTON DRIVE
WILMINGTON, MASSACHUSETTS 01887
(Address of principal executive offices, including ZIP code)
(978) 657-7500
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Securities Act (17
CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
ITEM 8.01 - OTHER EVENTS.
DUSA Pharmaceuticals, Inc. ("DUSA") issued a press release on the morning of
October 28, 2005, attached to and made a part of this report as Exhibit 99.1,
announcing the presentation of an independent investigator study in which
complete clearance of facial acne was observed in fourteen out of fourteen
patients treated with the combination of Levulan(R) (aminolevulinic acid HCl,
ALA) and Photodynamic Therapy with long pulse dye laser for recalcitrant
inflammatory acne vulgaris of the face. DUSA issued a second press release on
the afternoon of October 28, 2005, attached to and made a part of this report as
Exhibit 99.2, correcting and further clarifying certain information contained in
the earlier release, including, but not limited to, the quotation of Dr. Macrene
Alexiades-Armenakas provided therein.
Except for historical information, each news release contains certain
forward-looking statements that involve known and unknown risk and
uncertainties, which may cause actual results to differ materially from any
future results, performance or achievements expressed or implied by the
statements made. These forward-looking statements relate to the potential of the
therapy as safe and effective and as an alternative to isotretinoin, belief that
the therapy deserves a full development program, the publication of the study
results and the timing thereof, and the use of the product as first line
therapy. Furthermore, the factors that may cause differing results include the
publication by third-parties of the author's study results, the regulatory
process, the funding of clinical studies necessary to seek regulatory approval,
maintenance of patents and other risks identified in DUSA's SEC filings from
time to time.
ITEM 9.01 - FINANCIAL STATEMENT AND EXHIBITS
Item No. Description
99.1 Press Release, dated October 28, 2005
99.2 Press Release, as corrected, dated October 28, 2005
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
DUSA PHARMACEUTICALS, INC.
Dated: October 31, 2005 By: /s/ D. Geoffrey Shulman
---------------------------------
D. Geoffrey Shulman, MD, FRCPC
Chairman of the Board and Chief
Executive Officer
EXHIBIT INDEX
Item No. Description
99.1 Press Release, dated October 28, 2005
99.2 Press Release, as corrected, dated October 28, 2005